Records containing: Melanoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-15A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-04-15A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Study to Evaluate the Pharmacokinetic Profile, Efficacy, Safety and Immunogenicity of HLX18 vs. OPDIVO® (US-sourced OPDIVO®) in Multiple Resected Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-04-14Personalized Cancer Support for Young Adults
-
CLINICAL_TRIALS study record update · 2026-04-14Cell Harvest and Preparation for Surgery Branch Treatment Protocols
-
CLINICAL_TRIALS study record update · 2026-04-14TNF in Melanoma Patients Treated With Immunotherapy
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-04-13Phase I Pilot Study of RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
-
CLINICAL_TRIALS study record update · 2026-04-13Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance
-
CLINICAL_TRIALS study record update · 2026-04-13Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)
-
CLINICAL_TRIALS study record update · 2026-04-13An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-04-13Treatment of Visceral Localizations With Electrochemotherapy in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype: Monocenter, Single Arm, Clinical Investigation
-
CLINICAL_TRIALS study record update · 2026-04-13Cancer Moonshot Biobank Research Protocol
-
CLINICAL_TRIALS study record update · 2026-04-13A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-04-13A Phase I/II Study of TRK-950 in Patients With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-04-13A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Locally Advanced or Metastatic Cancers Following One or More Prior Therapies
-
CLINICAL_TRIALS study record update · 2026-04-13Molecular Analysis for Therapy Choice (MATCH)
-
CLINICAL_TRIALS study record update · 2026-04-09A Phase 2 Open-label, Two-cohort Study to Evaluate Patient Preference for Nivolumab + Relatlimab Fixed-dose Combination Subcutaneous Versus Nivolumab + Relatlimab Fixed-dose Combination Intravenous and Nivolumab Subcutaneous Versus Nivolumab Intravenous in Participants With Melanoma
-
CLINICAL_TRIALS study record update · 2026-04-09Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study
-
CLINICAL_TRIALS study record update · 2026-04-08A Multicenter, Phase II Clinical Trial of Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma (The ASPRIE-MM Study)
-
CLINICAL_TRIALS study record update · 2026-04-08A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B
-
CLINICAL_TRIALS study record update · 2026-04-08A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-04-08A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types (MK-3475A-F11)
-
CLINICAL_TRIALS study record update · 2026-04-07A Phase I Trial of Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
-
CLINICAL_TRIALS study record update · 2026-04-07CD8+ Cell Imaging During Neoadjuvant ImmunoTherapy (The C-IT Neo Trial)
-
CLINICAL_TRIALS study record update · 2026-04-07Blinded Reference Set for Multicancer Early Detection Blood Tests
-
CLINICAL_TRIALS study record update · 2026-04-07A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA